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Acute liver failure is a severe, but rare, out-
come of hepatitis A virus infection. Unusual
presentations of prevalent infections have of-
ten been attributed to pathogen-specific im-
mune deficits that exhibit Mendelian
inheritance. Genome-wide resequencing of un-
related cases has proven to be a powerful
approach for identifying highly penetrant risk
alleles that underlie such syndromes. Rare
mutations likely to affect protein expression or
function can be identified from sequence data,
and their association with a similarly rare
phenotype rests on their existence in multiple
affected individuals. A rare or novel sequence
variant that is enriched to a significant degree
in a genetically diverse cohort suggests a
candidate susceptibility allele. Whole genome
sequencing of ten individuals from ethnically
diverse backgrounds with HAV-associated
acute liver failure was performed. A set of
rational filtering criteria was used to identify
genetic variants that are rare in the population,
but enriched in this cohort. Single nucleotide
polymorphisms, insertions, and deletions were
considered and autosomal dominant, autoso-
mal recessive, and polygenic models were
applied. Analysis of the protein-coding exome
identified no single gene with putatively dele-
terious mutations shared by multiple individu-
als, arguing against a simple Mendelian model
of inheritance. A number of rare variants were
significantly enriched in this cohort, consistent
with a complex and genetically heterogeneous
trait. Several of the variants identified in this
genome-wide study lie within genes important
to hepatic pathophysiology and are candidate
susceptibility alleles for hepatitis A virus infec-
tion. J. Med. Virol. 86:1661–1668, 2014.
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INTRODUCTION
Hepatitis A virus (HAV) is a significant cause of
liver-related morbidity and mortality with an annual
incidence of up to 1.4 million cases worldwide
[Anon, 2013]. The clinical spectrum of HAV disease is
broad, ranging from asymptomatic seroconversion to
acute liver failure and death. Approximately one-
third of infections are clinically inapparent, and 30–
50% of those with symptoms require hospitalization
[Yang et al., 1988]. Severe infection leading to acute
liver failure is extremely rare, affecting <2% of
hospitalized patients and 0.015–0.3% of individuals
in large common-source epidemics [Cooksley, 2000;
Taylor et al., 2006].
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Risk factors for HAV acute liver failure remain
poorly defined. Disease severity is highly correlated
with the degree of hepatocellular necrosis in histolog-
ical specimens. Extreme presentations could therefore
result from either over-exuberant immune responses
or loss of initial virologic control, leading to greater
numbers of infected hepatocytes. The distribution of
clinical outcomes in common-source epidemics sug-
gests that the genotype and virulence of the infecting
strain play only a minor role, and most infections in
the United States are due to genotype IA [Ajmera
et al., 2011]. While advanced age, chronic hepatitis B
infection, and preexisting liver disease are correlated
with severe disease, many patients with acute liver
failure are young and without significant comorbid-
ities [Willner et al., 1998; Cooksley, 2000]. Genetic
polymorphisms in tumor necrosis factor alpha and
beta loci have been associated with fulminant hepati-
tis, and familial clusters of acute liver failure suggest
that host genetic factors are a significant contributor
to the clinical spectrum of HAV disease [Tsuchiya
et al., 2004; Yalniz et al., 2005; Ajmera et al., 2011].
Indeed, a case control study of individuals with HAV
associated acute liver failure identified a 6 amino
acid insertion within the virus’ cellular receptor,
TIM1/HAVCR1, as a susceptibility allele [Kim et al.,
2011].
Recent work indicates that severe outcomes of
prevalent infections are often due to Mendelian
deficits in immunity [Alcaı¨s et al., 2009]. Risk alleles
have typically been identified in children and often in
the setting of consanguinity. Healthy individuals are
known to carry many loss-of-function mutations, and
the role of these rare, high impact variants on more
common infections in adult populations has not been
extensively explored [Tennessen et al., 2012]. Ge-
nome-wide resequencing of unrelated cases with
extreme clinical presentations can be an effective
method for identifying these alleles [Ng et al., 2010].
Rare mutations likely to affect protein expression or
function can be identified from sequence data, and
their association with a similarly rare phenotype
rests on their existence in multiple affected individu-
als. A rare or novel sequence variant that is enriched
to a significant degree in a genetically diverse cohort
suggests a candidate susceptibility allele. In this
study, this approach was used to discover genetic
risk factors for severe outcomes of HAV infection.
MATERIALS AND METHODS
Patients and Samples
Individuals with HAV acute liver failure were
identified through the Acute Liver Failure Study
Group (ALFSG), a multicenter research collaboration.
The ALFSG database consists of over 2,000 adult
patients meeting pre-determined consensus criteria
for acute liver failure, defined as jaundice or illness
<26 weeks prior to admission and mental status
changes with coagulopathy (INR> 1.5), without
known chronic liver disease. HAV infection was
confirmed serologically by the clinical laboratory at
each study site at the time of enrollment (e.g., anti-
HAV IgM positivity) and deemed by the treating
medical team to be the primary cause of either acute
liver injury or acute liver failure in 39 patients
[Taylor et al., 2006]. The ALFSG provided genomic
DNA for eight subjects. Genomic DNA was also
provided by three additional subjects initially en-
rolled at the University of California, San Francisco
(UCSF) site. Informed, written consent was provided
by all subjects or their next of kin. The ALFSG study
protocols were reviewed and approved by the Institu-
tional Review Board (IRB) at each of the participat-
ing sites, and this study was approved by the IRBs of
the UCSF and the University of Michigan. This study
was performed according to the World Medical Asso-
ciation Declaration of Helsinki http://www.wma.net/e/
policy/b3.htm.
Sequencing and Variant Identification
Genomic DNA libraries were prepared and se-
quenced on the Illumina HiSeq platform using the
manufacturer’s reagents and protocols. Sequence
reads were aligned to the GRCh37 reference human
genome sequence using the Burrows–Wheeler Align-
ment Tool (BWA) paired end alignment algorithm
(BWT-SW). Picard and SAMtools were used to con-
vert the SAM alignment files into BAM format,
generate BAM indices, mark PCR duplicates, and
merge and divide sample-level BAM files into a
multisample, study-level BAM for each chromosome.
For each multi-sample, chromosomal BAM, local
realignment around InDels and base quality score
recalibration was performed with the Genome Analy-
sis Toolkit (GATK) version v2.2-16 as described in
the Broad Institute’s “Best Practice Variant Detection
with the GATK v4” guidelines. Multi-sample variant
calling was performed using the GATK UnifiedGeno-
typer. Variant call files (VCFs) were annotated with
snpEff using the GRCh37.64 ENSEMBL annotation
database. The GATK Variant Quality Score Recali-
bration feature was used to identify false-positive
variant calls, targeting quality control thresholds
that excluded fewer than 1% and 5% of known, high
confidence SNPs (HapMap3) and InDels (Mills De-
vine dataset), respectively. To identify stereotypical
sequence errors and mis-calls, whole genome sequen-
ces from three Center for the Study of Human
Polymorphism (CEPH) individuals (provided by
Illumina) were analyzed using an identical pipeline.
Filtering and Secondary Analysis
VCFs were imported into a MySQL database pre-
populated with tables containing reference genomic
data from both public and in-house sources. This
database included: estimates of allele frequency in
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various populations (derived from 1000 Genomes
data, dbSNP, NHLBI exomes, Complete Genomics
Public Genomes, in-house exomes, and three control
genomes provided by Illumina), lists of known pseu-
dogenes and immune genes, coordinates of repetitive
and redundant regions of the genome, and published
lists of genes with high loss-of-function rates. Further
details on the reference genomic data used and their
sources are provided as Supplementary Methods.
Variant calls were linked to these reference tables by
chromosome, position number, reference allele, and
alternate allele. Candidate genetic variants were
identified by applying a series of rational filters to
this linked dataset based on estimates of population
allele frequency, predicted biologic effect, genomic
context, and various modes of inheritance.
The appropriate allele frequency thresholds for
autosomal recessive and autosomal dominant models
of inheritance were calculated based on Hardy–Wein-
berg equilibrium with a conservatively estimated
trait prevalence of <2%. Unless otherwise specified,
predicted biologic effect was determined in a conser-
vative manner with consideration of all variants
likely to affect the translated polypeptide (e.g., non-
synonymous SNP, InDel, splice site variant, or start/
stop gain/loss). Only autosomal variants sequenced
to an average depth of 10 reads and passing the
VQSR threshold were considered. Single nucleotide
polymorphisms lying within 3 bp of a repetitive
region or segmental duplication were excluded, as
were InDels that extended to within 10 bp of such
features. Pseudogenes, genes reported to have high
predicted loss of function rates in the general popula-
tion, and genes known to commonly exist as false
positives in next generation sequencing datasets were
excluded. Variants passing these filters were then
ranked by the proportion of individuals harboring
the variant. For noncoding variants, putative regula-
tory function was based on an ENCODE Project
RegulomeDB score 5 and evolutionary conservation
was based on genome evolutionary rate profiling
(GERP) score. Genetic models applied (i.e., autosomal
recessive, single gene, single variant vs. autosomal
dominant, multiple genes, multiple variants) are
described in the results below and further details of
each database query are provided as Supplementary
Methods.
RESULTS
Thirty-nine individuals with HAV acute liver fail-
ure were identified from a multicenter registry and
genomic DNA was obtained from 11. Interim sequenc-
ing results identified one sample with an abnormally
high number of heterozygous genotype calls, suggest-
ing either contamination or chimerism. Further exam-
ination of study records revealed that, because of
clinical circumstances, DNA for this subject had been
collected post-liver transplant. This sample was ex-
cluded, and the characteristics of the final sequenced
cohort are described in Table I. All 10 individuals
were anti-HAV IgM positive, and 9 met criteria for
acute liver failure. Case 2 was not encephalopathic at
admission, and therefore, did not meet strict criteria
for acute liver failure. Data from this individual were
included in the analysis as the severity of his disease
was similar to the other cases (see Supplementary
Table SI). With the exception of Case 8, who was also
infected with HIV, none had significant medical
comorbidity. Four of the individuals were infected
with HAV genotype IA [Ajmera et al., 2011]. While
viral genotype information was not available on the
remaining individuals, previous work from this cohort
suggests that nearly all cases of acute liver failure at
the participating centers are due to genotype IA
[Ajmera et al., 2011]. The race/ethnicity of the cohort
was diverse with five non-Latino of European descent,
three Asians, and one Latino. Notably, the cohort
included a pair of first cousins (Cases 1 and 2) who
presented in close succession.
One hundred thirty-three gigabases of sequence
were generated per individual (Table II). On average,
95.5% of reference bases were covered at a read-depth
of 10 or greater, with a mean coverage of 93.9%
across RefSeq exons. In total, approximately three
TABLE I. Clinical Characteristics of Sequenced Cohort
Case 1a Case 2a Case 3 Case 4 Case 5 Case 6 Case 7 Case 8 Case 9 Case 10
Age 26 20 60 51 40 57 30 41 21 47
Gender M M F F M M F M F M
Race, ethnicity Asian Asian White White Latino White White White Asian White
Days from onset
to enrollment
6 8 24 7 9 8 50 13 9 11
History of liver
disease
No No No No No No No No No No
Anti‐HAV IgM þ þ þ þ þ þ þ þ þ þ
INR> 1.5 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Altered mental
status
Yes No Yes Yes Yes Yes Yes Yes Yes Yes
Peak encephalopathy
grade
III 0b IV IV IV IV I II III III
Outcome Transplant Spontaneous
survival
Transplant Spontaneous
survival
Spontaneous
survival
Transplant Transplant Transplant Spontaneous
survival
Transplant
nd, no data.
aFirst cousins.
bNot encephalopathic (acute liver injury).
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million SNPs (17,000–18,000 in coding regions) were
identified per individual, 1–2% of which were novel.
Between 600,000 and 700,000 InDels were observed
per individual (300–500 in coding regions), 5–12% of
which were novel. The observed transition to trans-
version ratio was 3.29–3.37 across coding regions and
2.12–2.13 across the genome as a whole. Concordance
between sequence variant calls and SNP genotype
calls was 99.94–99.97% in the seven samples for
which array-based genotypes were available. These
values are similar to those reported by others using
comparable pipelines [Pelak et al., 2010].
Filtering by allele frequency and functional impact
proved an efficient approach to identifying candidate
variants. By looking for variant loci shared among
these unrelated and ethnically diverse individuals, a
subset of rare, potentially deleterious polymorphisms
were prioritized from a total of eight million variants.
Autosomal recessive and autosomal dominant models
were considered separately, with the allele frequency
cut-offs for each based on an estimated trait frequency
of 2% and Hardy–Weinberg equilibrium [Cooksley,
2000; Taylor et al., 2006]. The filtering parameters are
detailed in Supplementary Methods, and the complete,
annotated outputs for each model are provided in
Supplementary Table SII.
Under a recessive model, no single coding polymor-
phism meeting all filtering criteria was identified in
more than one affected individual (Table III). The
racial and ethnic diversity of the cohort increased
the likelihood that individuals might harbor distinct
risk alleles in a common disease gene. Therefore, in a
second model, variants were grouped by transcript
and their combined effects examined at the gene
level. This analysis also identified no rare mutations
at the gene level that were shared among a majority
of cases. Finally, a polygenic model for HAV acute
liver failure was considered, with individual risk
alleles existing in a limited number of disease genes
that are not often shared among individuals. Using
this model, four candidate genes were identified that
had a single, homozygous non-synonymous SNP in
one individual each: natural killer cell cytotoxicity
receptor 3 ligand 1 (NCR3LG1), reelin (RELN),
syntaxin binding protein 1 (STXBP1), and tetratrico-
peptide repeat domain 40 (TTC40).
A parallel series of filters were applied to look at
dominant effects within the protein-coding exome. No
single coding variant was observed in more than 20%
of cases (Table III). Grouping variants by gene, no
candidate gene affecting more than 40% of cases
was identified. Because of the large number of
heterozygous variants shared among individuals,
particularly the first-cousin pair, an additional filter
was imposed when considering polygenic as opposed
to single-gene effects. This filter required that at
least two unrelated subjects were affected and that at
least one contributing variant was observed in multi-
ple individuals. Four candidate genes met these
criteria. Four individuals were heterozygous for one
of three rare missense mutations in glypican 1
(GPC1). Three individuals were heterozygous for one
of two rare missense mutations in macrophage stimu-
lating 1 receptor (MST1R). A similar distribution was
TABLE II. Summary Statistics on Whole Genome Sequence Data
Case 1 Case 2 Case 3 Case 4 Case 5 Case 6 Case 7 Case 8 Case 9 Case 10
Coverage statistics
All sites
Raw yield (Gb) 142.3 133.6 127.0 136.3 136.5 127.5 128.2 132.8 117.7 146.1
Aligned reads (Gb) 123.5 115.9 111.6 120.2 120.3 112.0 111.8 115.7 103.2 129.4
Coverage 10 95.4% 95.2% 95.7% 96.0% 95.1% 94.9% 95.7% 95.3% 96.0% 96.1%
Codinga
Coverage 10 93.3% 92.8% 92.8% 93.8% 92.4% 92.3% 93.0% 94.4% 96.9% 97.0%
SNP statistics
All sites
SNPs 3,188,561 3,181,072 3,151,179 3,158,296 3,172,525 3,113,583 3,148,716 3,106,186 3,199,635 3,092,950
% Novelb 2.49% 2.44% 0.90% 1.06% 0.98% 0.97% 0.97% 0.88% 1.96% 0.86%
Ti/Tv 2.12 2.12 2.12 2.12 2.12 2.12 2.12 2.13 2.12 2.13
Codinga
SNPs 19,019 18,922 18,490 18,839 18,873 18,397 18,616 18,665 18,748 18,399
% Novelb 2.73% 2.71% 0.89% 1.05% 1.25% 0.88% 0.95% 0.81% 2.09% 0.71%
Ti/Tv 3.34 3.33 3.35 3.36 3.33 3.29 3.37 3.31 3.3 3.37
InDel statistics
All sites
InDels 705,851 703,504 701,111 705,163 705,434 696,876 701,599 689,105 689,441 672,362
% Novelb 8.04% 7.90% 7.50% 7.62% 7.50% 7.51% 7.43% 7.37% 7.43% 7.03%
Codinga
InDels 411 395 398 393 392 390 384 420 466 453
% Novelb 7.79% 9.37% 5.28% 4.83% 6.89% 4.36% 4.69% 7.38% 11.80% 8.39%
aRefSeq.
bdbSNP 137.
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observed in dynein axonemal heavy chain 12
(DNAH12). Finally, two unrelated individuals
were heterozygous for a 9-bp insertion in nuclear
factor of activated T-cells, calcineurin-dependent 4
(NFATC4). None of these alleles were identified in
dbSNP137, the 1000 genomes project integrated
phase 1 release, or the 54 unrelated genomes in the
Complete Genomics public database. Screenshots of
the primary sequencing data supporting the variant
calls at each of the coding loci are shown in
Supplementary Figure S1.
A six amino acid insertion within TIM1/HAVCR,
the gene encoding the HAV receptor, has been
previously identified as a risk factor for acute liver
failure in a case control study [Kim et al., 2011]. This
insertion, 157insMTTTVP, is now annotated as the
reference allele in build 37 of the human genome.
None of our 10 cases were homozygous for this risk
allele, and 6 individuals were heterozygous.
A large number of rare noncoding variants were
found within our cohort (Table II). Because of the
large number of variants, a more stringent acute
liver failure trait frequency threshold of 0.5% was
used in the analysis of these alleles. This adjustment
was required to achieve a more actionable list of
candidate variants and the selected frequency esti-
mate remains within the range supported by epide-
miologic studies. Only SNPs were considered in
analyses of noncoding variants, because of pipeline-
specific biases related to accurate InDel identifica-
tion. Despite the use of more restrictive filtering
thresholds and in contrast to the results for protein-
coding sequences described above, a large number of
rare, noncoding variants were shared among subjects.
Under a recessive model, 225 SNPs were identified
that were shared between two or more individuals in
the cohort, 68 of which existed in a homozygous state
in more than half of the cases. In an autosomal
dominant model, 1,124 candidate variants met initial
filtering criteria (Fig. 1).
The number of SNPs shared by these unrelated
individuals was much larger than expected, even for
noncoding regions of the genome. Because intergenic
sequences of the reference genome can be more
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Fig. 1. Noncoding variants shared among individuals by
mode of inheritance. Shown are number of single nucleotide
variants present at each allele frequency assuming either an
autosomal recessive (top) or autosomal dominant (bottom) model
of inheritance in each of the ten individuals sequenced. Gray
bars indicate the number of variants identified using basic
frequency cutoffs described in text and Supplementary Meth-
ods. Black bars indicate the number of variants remaining after
filtering out those present in any of the three control genomes.
TABLE III. Candidate Genes by Genetic Model
Model typea Autosomal recessiveb Autosomal dominantb
Single, coding variant None None
Single gene, multiple coding variants None None
Multiple genes, multiple coding variants NCR3LG1 GPC1
RELN MST1R
STXBP1 DNAH12
TTC40 NFATC4
Single, noncoding variant 45 variants near 25 genes 735 variants near 551 genes
Regulatory or evolutionary conserved region 13 variants near 7 genes 358 variants near 291 genes
(Regulatory OR conserved)
AND near immune, inflammatory,
apoptotic, or hepatitis gene
None 13 variants near 12 genes
aSee Supplementary Methods for details of filtering criteria.
bSee Supplementary Table SII for complete, annotated lists of variants by model. Data are for SNPs not found in three control CEPH
genomes. The total number of SNPs identified is reported in the text.
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stereotyped and have been less well characterized,
current technologies are more prone to systematic
errors in alignment and annotation in these regions.
Such errors tend to be specific to the particular
combination of sequencing platform, reference ge-
nome, alignment, and variant calling tools used. To
identify systematic sequencing errors in the variant
call set, data from three individuals in the CEPH
cohort were used. The genomes of these individuals
were sequenced in the same laboratory and analyzed
in an identical manner.
When presumed “false-positive” susceptibility var-
iants identified among these three randomly selected
control genomes were removed, a much smaller num-
ber of noncoding SNPs were shared among individuals
in our cohort (Fig. 1). As anticipated, variant calls
from coding regions of the genome were essentially
unaffected and none of the candidate alleles identified
in coding analyses were observed in the six CEPH
chromosomes (Supplementary Table SII). After this
final filtering step, 45 noncoding SNPs met basic
criteria under an autosomal recessive model, 3 of
which (TFCP2, LRP1B, and KRT13) existed in a
homozygous state in more than half of the cases
(Table III). In an autosomal dominant model, 735
single nucleotide variants were identified that were
shared between 2 individuals in the cohort. As ex-
pected, there was a significant decrease in the number
of alleles shared by more than 2 individuals with just
23 alleles present at a minor allele frequency of 30%.
To further explore those most likely to have biolog-
ic effects, the resultant candidate list was compared
with reference databases annotated for regulatory
elements, evolutionary conservation, and gene func-
tion (see Supplementary Methods). Of the 45 noncod-
ing SNPs found in the autosomal recessive analysis,
13 were in regulatory or evolutionarily conserved
regions of the genome. In an autosomal dominant
model, 358 SNPs were identified, 13 of which lay in
or near one of 2,525 genes reported to play a role in
hepatitis or other immune, inflammatory, and apo-
ptotic processes (see Supplementary Methods). Only
1 of these 13, an intronic SNP in AKT1, was shared
by more than 2 individuals (Table III and Supple-
mentary Table SII).
DISCUSSION
Increased susceptibility to many common infectious
diseases may be mediated by pathogen-specific defi-
cits in host immunity [Alcaı¨s et al., 2009]. Large-scale
sequencing efforts indicate that healthy individuals
harbor many occult loss-of-function variants [Tennes-
sen et al., 2012], and the phenotypic impact of these
rare variants on infectious outcome may only be
revealed upon exposure to the appropriate agent. In
many cases, candidate gene resequencing across
consanguineous pedigrees has identified autosomal
recessive alleles responsible for these pathogen-
specific deficits. Next generation sequencing of unre-
lated individuals has accelerated the discovery of
similarly penetrant alleles in situations where pedi-
grees are not available.
This genetic model for infectious disease suscepti-
bility was applied to HAV acute liver failure, a rare
outcome of a relatively common viral infection. Given
prior results with similarly rare diseases, it was
reasonable to hypothesize that the risk of HAV acute
liver failure might be explained by a single suscepti-
bility locus across an ethnically diverse collection of
patients. However, the results presented in this study
suggest that genetic susceptibility to hepatitis A is a
heterogeneous and complex trait. While only 10
genomes were analyzed, other studies have success-
fully identified Mendelian risk alleles by sequencing
fewer individuals [Ng et al., 2010]. More likely, these
results suggest that genetic susceptibility to hepatitis
A is a heterogeneous and complex trait. The identifi-
cation of multiple candidate risk alleles shared by
several individuals each suggests that the immunopa-
thogenesis of HAV is modulated by more than one
biological pathway. Alternatively, the genetic archi-
tecture of HAV susceptibility may differ in adults, as
most Mendelian risk alleles for infectious diseases
have been identified in children. A notable caveat of
this study is that the effects of sex chromosomes,
epigenetic factors, or copy number variants were not
considered.
Despite the apparent complexity of HAV suscepti-
bility, a handful of candidate variants were identified,
several of which exist within biologically plausible
loci. Each of these mutations is rare in the general
population, and many impact the amino acid se-
quence of proteins important to hepatic physiology.
MST1R is a cell surface receptor tyrosine kinase that
regulates hepatic immune responses and is expressed
on tissue macrophages and hepatocytes. Its ligand is
the hepatocyte growth factor-like (HGFL) protein and
MST1R knockout mice are more susceptible to acute
liver injury [McDowell et al., 2002]. NCR3LG1 is a
ligand for natural killer cell receptors and appears to
play an immunomodulatory role in response to TLR
and pro-inflammatory cytokine signaling [Matta
et al., 2013]. NFATC4, a regulator of T cell and
innate immune responses, is highly expressed in the
liver, and knockout mice are less susceptible to
alcoholic-mediated liver damage [Bukong et al.,
2011]. GPC1 is a glycophosphatidylinositol (GPI)
linked cell surface protein and member of a large
group of heparan sulfate binding proteins that are
involved in morphogenesis, adhesion, chemotaxis,
and inflammation [Fransson, 2003; Parish, 2006].
Heparan sulfate proteoglycans are key cell surface
attachment sites for infectious agents and are
thought to play a role in the hepatotropism of
hepatitis B virus, hepatitis C virus, and hepatitis D
[Barth et al., 2003; Schulze et al., 2007; Leistner
et al., 2008; Longarela et al., 2013; Shi et al., 2013].
In contrast, the functions of several of the identified
genes do not immediately suggest a role in HAV
J. Med. Virol. DOI 10.1002/jmv
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pathogenesis. Mutations in RELN and STXBP1 have
only been associated with neurological disorders, and
there are insufficient data to suggest a mechanistic
link between DNAH12 and HAV susceptibility. There
was little evidence for enrichment of the previously
identified HAV risk allele, TIM1-157insMTTTVP,
within our cohort [Kim et al., 2011]. The frequency of
the allele among our cases was more similar to the
controls in this study. This difference could be due to
racial or ethnic differences in the study population.
It was surprising to find a significant number of
noncoding variants shared by multiple members of a
genetically diverse cohort. In many cases, these
variants are either very rare (allele frequency <1%)
or not found in dbSNP and the 54 genomes in the
Complete Genomics public dataset. Many of these
variants, however, were identified in the sequences of
three control genomes analyzed with the same bioin-
formatic pipeline. These data suggest that many
noncoding variants annotated as rare or novel in
public databases may be more frequent than previ-
ously realized. Alternatively, systematic biases in the
sequencing platform utilized could result in experi-
ment-specific false-positive variant calls. These re-
sults highlight a significant challenge in identifying
causative variants in whole genome as opposed to
exome sequence. In the analysis of coding regions, a
number of false-positive susceptibility alleles were
filtered out based on their presence in large public
databases of coding sequence as well as exomes
sequenced by the authors’ laboratories for other
studies. While the cost and availability of whole
genome sequence precluded a similarly efficient ap-
proach to noncoding variants, analogous control sam-
ple filtering strategies should be possible in the near
future.
This study is the most comprehensive study of
human genetic susceptibility to HAV to date and
represents an important step toward defining the
biological pathways involved in HAV pathogenesis.
The rarity of the identified variants and the corre-
sponding phenotype suggests that validating the
results through traditional association studies will be
difficult. For example, an adequately powered ge-
nome-wide association study would require hundreds
or thousands of cases and controls. Rather, one
expects that sequencing additional cases will confirm
some of the findings and may identify additional risk
alleles for this apparently complex trait. The signifi-
cance of the most plausible candidates can also be
evaluated in cell-based assays for HAV infection and
small animal models.
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Baylor University Medical Center, Dallas, TX; A.
Obaid S. Shaikh, M.D., University of Pittsburgh,
Pittsburgh, PA; Andres Blei, M.D., Northwestern
University, Chicago, IL (deceased), Daniel Ganger,
M.D., Northwestern University, Chicago, IL; Atif
Zaman, M.D., University of Oregon, Portland, OR;
Steven H.B. Han, M.D., University of California, Los
Angeles, CA; Robert Fontana, M.D., University of
Michigan, Ann Arbor, MI; Brendan McGuire, M.D.,
University of Alabama, Birmingham, AL; Raymond
T. Chung, M.D., Massachusetts General Hospital,
Boston, MA; Alastair Smith, M.B., Ch.B., Duke
University Medical Center, Durham, NC; Robert
Brown, M.D., Cornell/Columbia University, New
York, NY; Jeffrey Crippin, M.D., Washington Univer-
sity, St. Louis, MO; Edwyn Harrison, Mayo Clinic,
Scottsdale, AZ; Adrian Reuben, M.B.B.S., Medical
University of South Carolina, Charleston, SC; San-
tiago Munoz, M.D., Albert Einstein Medical Center,
Philadelphia, PA; Rajender Reddy, M.D., University
of Pennsylvania, Philadelphia, PA; R. Todd Stravitz,
M.D., Virginia Commonwealth University, Richmond,
VA; Lorenzo Rossaro, M.D., University of California
Davis, Sacramento, CA; Raj Satyanarayana, M.D.,
Mayo Clinic, Jacksonville, FL; and Tarek Hassanein,
M.D., University of California, San Diego, CA. The
University of Texas Southwestern Administrative
Group included Grace Samuel, Ezmina Lalani, Carla
Pezzia, Corron Sanders, Ph.D., Nahid Attar, Linda S.
Hynan, Ph.D. and Angela Bowling and the Medical
University of South Carolina Data Coordination Unit
included Valerie Durkalski, Ph.D., Wenle Zhao,
Ph.D., Catherine Dillon, Holly Battenhouse, Tomoko
Goddard, Lynn Patterson, Jaime Speiser, and Caitlyn
Nicole Ellerbe.
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